Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00272558|
Recruitment Status : Completed
First Posted : January 6, 2006
Last Update Posted : September 18, 2009
|Condition or disease||Intervention/treatment||Phase|
|Malignant Pleural Mesothelioma||Drug: Carboplatin and Vinorelbine||Phase 2|
Chemotherapy with carboplatin i.v. day one in each cycle Vinorelbine i.v. day one, and orally day 8 in each cycle, repeat new cycle every 3 weeks. Total of 6 cycles.
Endpoint is response rate, secondary endpoints survival and toxicity.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma|
|Study Start Date :||September 2004|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00272558
|Dept. Oncol., Rigshospitalet|
|Copenhagen, Denmark, 2100|
|Study Chair:||Jens B Sorensen, MD||Dept. Oncology, Rigshospitalet|